Jenburkt Pharmaceuticals Ltd
Jenburkt Pharmaceuticals Ltd (JENBURPH) last traded at ₹1,034, a market capitalisation of ₹456 crore, on a P/E of 12.8. Over the past 52 weeks the stock has ranged between ₹944 and ₹1,321. Jenburkt Pharmaceuticals Ltd last reported results for the quarter ended Jun 2026, with sales of ₹35.51 crore and net profit of ₹5.89 crore. Jenburkt Pharmaceuticals Ltd’s annual general meeting is scheduled for 4 Sept 2026. Figures are as of 25 Aug 2026 and are not real time.
Jenburkt Pharmaceuticals Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Jenburkt Pharmaceuticals Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹35.51 cr, down 0.1% from ₹35.53 cr a year earlier. Net profit was ₹5.89 cr, down 24.4% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 41.22 | 36.89 | 41.05 | 35.53 | 45.56 | 43.02 | 44.63 | 35.51 |
| Expenses | 29.79 | 28.07 | 30.19 | 26.58 | 32.45 | 35.59 | 30.38 | 29.48 |
| Operating profit | 11.43 | 8.82 | 10.86 | 8.95 | 13.11 | 7.43 | 14.25 | 6.03 |
| OPM % | 27.73% | 23.91% | 26.46% | 25.19% | 28.78% | 17.27% | 31.93% | 16.98% |
| Other income | 1.85 | 1.58 | 1.88 | 2.06 | 2.08 | 1.82 | 0.4 | 1.51 |
| Interest | 0.12 | 0.11 | 0.11 | 0.11 | 0.11 | 0.12 | 0.13 | 0.13 |
| Depreciation | 0.64 | 0.78 | 0.79 | 0.72 | 0.74 | 0.83 | 0.81 | 0.64 |
| Profit before tax | 12.52 | 9.51 | 11.84 | 10.18 | 14.34 | 8.3 | 13.71 | 6.77 |
| Tax % | 23.32% | 31.65% | 27.87% | 23.48% | 29.08% | 28.55% | 20.86% | 13.00% |
| Net profit | 9.6 | 6.51 | 8.54 | 7.79 | 10.16 | 5.93 | 10.85 | 5.89 |
| EPS (₹) | 21.75 | 14.75 | 19.35 | 17.65 | 23.02 | 13.44 | 24.58 | 13.35 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Jenburkt Pharmaceuticals Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 109 | 124 | 137 | 142 | 152 | 169 | 169 |
| Operating profit | 20 | 27 | 30 | 33 | 40 | 44 | 41 |
| OPM % | 18% | 22% | 22% | 23% | 27% | 26% | 24% |
| Net profit | 16 | 22 | 25 | 26 | 32 | 35 | 33 |
| EPS (₹) | 35.95 | 48.59 | 55.76 | 58.87 | 72.64 | 78.72 | 74.39 |
TTM is the trailing twelve months to the most recent quarter.
Jenburkt Pharmaceuticals Ltd growth and returns
- 10 Years
- 6%
- 5 Years
- 9%
- 3 Years
- 7%
- TTM
- 9%
- 10 Years
- 13%
- 5 Years
- 18%
- 3 Years
- 15%
- TTM
- 10%
- 10 Years
- 11%
- 5 Years
- 15%
- 3 Years
- 14%
- 1 Year
- -9%
- 10 Years
- 21%
- 5 Years
- 20%
- 3 Years
- 20%
- Last Year
- 20%
Jenburkt Pharmaceuticals Ltd shareholding pattern
Promoters held 46.62% at Jun 2026, broadly unchanged since Jun 2025. FIIs 0.00% and DIIs 0.12%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 46.71% | 46.69% | 46.68% | 46.67% | 46.66% | 46.65% | 46.64% | 46.62% |
| FIIs | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DIIs | 0.00% | 0.12% | 0.12% | 0.12% | 0.12% | 0.12% | 0.12% | 0.12% |
| Public | 53.28% | 53.20% | 53.20% | 53.21% | 53.22% | 53.24% | 53.24% | 53.27% |
| No. of shareholders | 6,628 | 6,901 | 6,987 | 6,712 | 6,855 | 7,163 | 6,999 | 7,103 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
When is Jenburkt Pharmaceuticals Ltd’s AGM?
Jenburkt Pharmaceuticals Ltd’s annual general meeting is scheduled for 4 Sept 2026.
- AGM41st Annual General Meeting to transact business as per notice
See the full results calendar for every Indian company reporting in the next 30 days.
Jenburkt Pharmaceuticals Ltd corporate filings
- Newspaper Publication for standalone Unaudited Financial Results for the quarter ended on 30th June, 2026.Company Updatelow impact
Cruxal's analysis: Jenburkt Pharmaceuticals Limited has fulfilled its regulatory obligation under SEBI…
Read the full analysis - Outcome of the Board Meeting held today on 06th August, 2026.Board Meetinghigh impact
Cruxal's analysis: Jenburkt Pharmaceuticals Limited reported a challenging first quarter for FY27, with…
Read the full analysis - Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, we are enclosing herewith clippings of the Newspaper publication for Notice of the 41st AGM of the Company.Company Updatelow impact
Cruxal's analysis: Jenburkt Pharmaceuticals Limited has announced the scheduling of its 41st Annual General…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Jenburkt Pharmaceuticals Ltd
Cruxal reads every Jenburkt Pharmaceuticals Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.